Valuation: CorMedix Inc.

Market Cap 661M 579M 535M 492M 929M 63.7B 944M 6.4B 2.51B 31.17B 2.48B 2.43B 107B P/E 2026 *
15.4x
P/E 2027 * 88.4x
Enterprise Value 661M 579M 535M 492M 929M 63.7B 944M 6.4B 2.51B 31.17B 2.48B 2.43B 107B EV / Sales 2026 *
1.97x
EV / Sales 2027 * 2.32x
Free-Float
92.47%
Yield 2026 *
-
Yield 2027 * -
1 day-7.60%
1 week-6.49%
Current month-0.89%
1 month-10.27%
3 months+2.64%
6 months+13.08%
Current year-33.10%
1 week 7.69
Extreme 7.69
8.53
1 month 7.5
Extreme 7.495
9.06
Current year 6.12
Extreme 6.125
12.29
1 year 6.12
Extreme 6.125
14.96
3 years 2.57
Extreme 2.57
17.43
5 years 2.57
Extreme 2.57
17.43
10 years 0.86
Extreme 0.8605
18.8
Manager TitleAgeSince
Chief Executive Officer 50 10/05/2022
Director of Finance/CFO 54 29/08/2025
Compliance Officer 66 12/12/2023
Director TitleAgeSince
Director/Board Member 67 06/08/2015
Chairman 81 03/08/2017
Director/Board Member 70 16/08/2011
Date Insider Type Main position Quantity % Market Cap.
2/4/26 A Free

General Counsel

36,006 0.0457%
2/4/26 A Free

Chief Executive Officer

77,156 0.0979%
2/4/26 A Free

Chief Operating Officer

36,006 0.0457%
Change 5-day change 1-year change 3-year change Capi.($)
-7.60%-6.49%-28.36%+103.66% 661M
-2.43%+0.30%+55.58%+14.70% 315B
-0.99%-3.50%+22.02%-10.98% 67.81B
-0.93%+1.29%+36.56%+81.09% 9.23B
+1.32%+1.01%+8.41%-0.52% 8.56B
-3.27%-3.15%-25.44%-10.07% 4.18B
+0.12%-10.11%-7.91%+17.37% 3.59B
-2.26%+1.62%-47.58%+20.90% 3.55B
-1.29%+0.15%+46.63%+54.71% 2.79B
+3.79%+0.83%+7.85%-21.58% 2.09B
Average -1.36%-2.32%+6.78%+24.93% 41.74B
Weighted average by Cap. -2.04%+1.73%+46.07%+11.73%

Financials

2026 *2027 *
Net sales 335M 293M 271M 249M 470M 32.26B 478M 3.24B 1.27B 15.79B 1.26B 1.23B 54.39B 285M 250M 231M 213M 401M 27.5B 407M 2.76B 1.08B 13.46B 1.07B 1.05B 46.37B
Net income 47.14M 41.32M 38.19M 35.13M 66.28M 4.55B 67.34M 457M 179M 2.22B 177M 173M 7.66B 8.61M 7.55M 6.98M 6.42M 12.11M 830M 12.3M 83.41M 32.7M 406M 32.33M 31.63M 1.4B
Net Debt - -
Logo CorMedix Inc.
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
Employees
191
Date Price Change Volume
20/07/26 $7.780 -7.60% 1,155,976
17/07/26 $8.420 +1.57% 694,737
16/07/26 $8.290 -1.54% 874,704
15/07/26 $8.420 +1.81% 648,439
14/07/26 $8.270 -0.60% 806,842
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
7.780USD
Average target price
15.00USD
Spread / Average Target
+92.80%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CRMD Stock